{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:38:55Z","timestamp":1793716735259,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003399","name":"science and technology commission of shanghai municipality","doi-asserted-by":"publisher","award":["19401970300"],"award-info":[{"award-number":["19401970300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Clinical Research Plan of SHCD","award":["SHD2020CR2049B"],"award-info":[{"award-number":["SHD2020CR2049B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperlipidemia has become a common chronic disease worldwide in recent years. Studies have shown that hyperlipidemia patients, especially those with a high level of serum low-density lipoprotein cholesterol (LDL-C), have a significantly higher prevalence of atherosclerosis, leading to coronary heart disease. Previous basic experiments and clinical studies have shown that Qushi Huayu granules (QSHY) reduce blood lipids in patients with non-alcoholic fatty liver disease (NAFLD) accompanied by hyperlipidemia. However, the clinical efficacy of QSHY in patients with hyperlipidemia is still lacking. This study aims to investigate the effect and safety of QSHY for hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a randomized, double-blind, placebo-controlled trial. A total of 210 participants will be enrolled and randomized into the QSHY or placebo granules groups in equal proportions, who will receive treatment for 24\u2009weeks. The primary outcome will be the change in LDL-C from baseline to week 12. Secondary outcomes will be changes in other serum lipids markers, life quality measuring health surveys, and traditional Chinese medicine (TCM) pattern scale. All related tests will be measured at baseline, week 12, and week 24 after enrollment. Adverse events and the safety of intervention will be monitored and evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We designed a clinical trial of hyperlipidemia management with QSHY, a TCM prescription. The results of this trial will present the efficacy and safety of QSHY in patients with hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Chinese Clinical Trial Registry\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=47758\">ChiCTR2000034125<\/jats:ext-link>\n                      . Registered on June 25, 2019\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06031-3","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:02:59Z","timestamp":1643778179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuanlong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maojun","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2208-2882","authenticated-orcid":false,"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"issue":"9 Suppl","key":"6031_CR1","first-page":"S139","volume":"23","author":"S Karr","year":"2017","unstructured":"Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):S139\u2013S48.","journal-title":"Am J Manag Care"},{"issue":"10","key":"6031_CR2","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"E Benjamin","year":"2019","unstructured":"Benjamin E, Muntner P, Alonso A, Bittencourt M, Callaway C, Carson A, et al. Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56\u2013e528.","journal-title":"Circulation"},{"issue":"5","key":"6031_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.6515\/ACS.201809_34(5).20180629A","volume":"34","author":"Y Li","year":"2018","unstructured":"Li Y, Chao T, Liu P, Ueng K, Yeh H. Lipid lowering therapy for acute coronary syndrome and coronary artery disease: highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. Acta Cardiologica Sinica. 2018;34(5):371\u20138. https:\/\/doi.org\/10.6515\/ACS.201809_34(5).20180629A.","journal-title":"Acta Cardiologica Sinica"},{"issue":"1","key":"6031_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12872-016-0300-9","volume":"16","author":"M Cybulsky","year":"2016","unstructured":"Cybulsky M, Cook S, Kontsevaya A, Vasiljev M, Leon D. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia. BMC Cardiovasc Disord. 2016;16(1):122. https:\/\/doi.org\/10.1186\/s12872-016-0300-9.","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"6031_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655\u201366. https:\/\/doi.org\/10.1016\/S2213-8587(13)70191-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6031_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacl.2021.01.008","volume":"22","author":"RA Birnbaum","year":"2021","unstructured":"Birnbaum RA, Horton BH, Gidding S, Brenman LM, Avins AL. Closing the gap: identification and management of familial hypercholesterolemia in an integrated healthcare delivery system. J Clin Lipidol. 2021;22(2):347\u201357. https:\/\/doi.org\/10.1016\/j.jacl.2021.01.008.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"6031_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1161\/CIRCOUTCOMES.109.910711","volume":"3","author":"A Moran","year":"2010","unstructured":"Moran A, Gu D, Zhao D, Coxson P, Wang Y, Chen C, et al. Future cardiovascular disease in china: Markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Q Outcome. 2010;3(3):243\u201352. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.109.910711.","journal-title":"Circ Cardiovasc Q Outcome"},{"issue":"S1","key":"6031_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11789-015-0074-0","volume":"10","author":"G Schmitz","year":"2015","unstructured":"Schmitz G, Ors\u00f3 E. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin Res Cardiol Suppl. 2015;10(S1):21\u20135. https:\/\/doi.org\/10.1007\/s11789-015-0074-0.","journal-title":"Clin Res Cardiol Suppl"},{"key":"6031_CR9","doi-asserted-by":"publisher","first-page":"560958","DOI":"10.3389\/fphar.2020.560958","volume":"11","author":"K Arnesen","year":"2020","unstructured":"Arnesen K, Phung A, Randsborg K, Mork I, Thorvall M, Langslet G, et al. Risk of recurrent coronary events in patients with familial hypercholesterolemia; a 10-years prospective study. Front Pharmacol. 2020;11:560958. https:\/\/doi.org\/10.3389\/fphar.2020.560958.","journal-title":"Front Pharmacol"},{"issue":"19","key":"6031_CR10","first-page":"4386","volume":"21","author":"X Lian","year":"2017","unstructured":"Lian X, Zhang Y, Li X, Jing L, Cairang Z, Gou J. Exploration on the relationship between the elderly osteoporosis and cardiovascular disease risk factors. Eur Rev Med Pharmacol Sci. 2017;21(19):4386\u201390.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"6031_CR11","doi-asserted-by":"crossref","unstructured":"Chang HJ, Lin KR, Chang JL, Lin MT. Risk factors for chronic kidney disease in older adults with hyperlipidemia and\/or cardiovascular diseases in Taipei City, Taiwan: a community-based cross-sectional analysis. Int J Environ Res Public Health. 17(23):8763.","DOI":"10.3390\/ijerph17238763"},{"issue":"22","key":"6031_CR12","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","volume":"42","author":"T Speer","year":"2021","unstructured":"Speer T, Ridker PM, Eckardstein AV, Schunk SJ, Fliser D. Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J. 2021;42(22):2170\u201385. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1050.","journal-title":"Eur Heart J"},{"issue":"4","key":"6031_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.pan.2016.02.011","volume":"16","author":"R Carr","year":"2016","unstructured":"Carr R, Rejowski B, Cote G, Pitt H, Zyromski N. Systematic review of hypertriglyceridemia-induced acute pancreatitis: a more virulent etiology? Pancreatology. 2016;16(4):469\u201376.","journal-title":"Pancreatology"},{"issue":"11","key":"6031_CR14","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC201712050","volume":"167","author":"L Kopin","year":"2017","unstructured":"Kopin L, Lowenstein C. Dyslipidemia. Ann Int Med. 2017;167(11):ITC81\u201396. https:\/\/doi.org\/10.7326\/AITC201712050.","journal-title":"Ann Int Med"},{"issue":"1","key":"6031_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer K, Ginsberg H, Hegele R. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99\u2013109c.","journal-title":"Eur Heart J"},{"issue":"1","key":"6031_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000000580","volume":"138","author":"A Volgman","year":"2018","unstructured":"Volgman A, Palaniappan L, Aggarwal N, Gupta M, Khandelwal A, Krishnan A, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation. 2018;138(1):e1\u2013e34. https:\/\/doi.org\/10.1161\/CIR.0000000000000580.","journal-title":"Circulation"},{"key":"6031_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"A Catapano","year":"2016","unstructured":"Catapano A, Graham I, De Backer G, Wiklund O, Chapman M, Drexel H, et al. 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281\u2013344. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.018.","journal-title":"Atherosclerosis"},{"issue":"5","key":"6031_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4155\/fmc-2018-0294","volume":"11","author":"A Lavecchia","year":"2019","unstructured":"Lavecchia A, Cerchia C. Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy. Future Med Chem. 2019;11(5):423\u201341. https:\/\/doi.org\/10.4155\/fmc-2018-0294.","journal-title":"Future Med Chem"},{"issue":"10","key":"6031_CR19","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1080\/17425247.2020.1792439","volume":"17","author":"A Suresh","year":"2020","unstructured":"Suresh A, Narayan R, Nayak U. Recent advances in the development of asenapine formulations. Expert Opin Drug Deliv. 2020;17(10):1377\u201393. https:\/\/doi.org\/10.1080\/17425247.2020.1792439.","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"6031_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/17425255.2020.1749261","volume":"16","author":"B Tomlinson","year":"2020","unstructured":"Tomlinson B, Chan P, Zhang Y, Liu Z, Lam C. Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2020;16(5):371\u201385. https:\/\/doi.org\/10.1080\/17425255.2020.1749261.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"18","key":"6031_CR21","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1001\/jama.291.18.2243","volume":"291","author":"J Walsh","year":"2004","unstructured":"Walsh J, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291(18):2243\u201352. https:\/\/doi.org\/10.1001\/jama.291.18.2243.","journal-title":"JAMA"},{"issue":"11","key":"6031_CR22","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1001\/jama.2013.276734","volume":"310","author":"J McEvoy","year":"2013","unstructured":"McEvoy J, Blumenthal R, Blaha M. Statin therapy for hyperlipidemia. JAMA. 2013;310(11):1184\u20135. https:\/\/doi.org\/10.1001\/jama.2013.276734.","journal-title":"JAMA"},{"issue":"4","key":"6031_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1254\/jphs.13R06CP","volume":"123","author":"K Sakamoto","year":"2013","unstructured":"Sakamoto K, Kimura J. Mechanism of statin-induced rhabdomyolysis. J Pharmacol Sci. 2013;123(4):289\u201394. https:\/\/doi.org\/10.1254\/jphs.13R06CP.","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"6031_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","volume":"17","author":"S Bellosta","year":"2018","unstructured":"Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17(1):25\u201337. https:\/\/doi.org\/10.1080\/14740338.2018.1394455.","journal-title":"Expert Opin Drug Saf"},{"key":"6031_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.12659\/AJCR.914707","volume":"20","author":"M Mohamed","year":"2019","unstructured":"Mohamed M, Salameh O, Saeed A. Statin-induced rhabdomyolysis, acute kidney injury, and hepatitis leading to death. Am J Case Rep. 2019;20:709\u201312. https:\/\/doi.org\/10.12659\/AJCR.914707.","journal-title":"Am J Case Rep"},{"issue":"6","key":"6031_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/20009666.2019.1702272","volume":"9","author":"P Sharma","year":"2019","unstructured":"Sharma P, Timilsina B, Adhikari J, Parajuli P, Dhital R, Tachamo N. Statin-induced necrotizing autoimmune myopathy: an extremely rare adverse effect from statin use. J Commun Hosp Int Med Perspect. 2019;9(6):503\u20136. https:\/\/doi.org\/10.1080\/20009666.2019.1702272.","journal-title":"J Commun Hosp Int Med Perspect"},{"issue":"3","key":"6031_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.pcd.2019.08.005","volume":"14","author":"Y Kim","year":"2020","unstructured":"Kim Y, Han Y, Choi E, You N, Lee J, You H, et al. Statin use increased new-onset diabetes in hypercholesterolemic individuals: data from the Korean National Health Insurance Service-National Health Screening Cohort database (NHIS-HEALS). Prim Care Diabetes. 2020;14(3):246\u201353. https:\/\/doi.org\/10.1016\/j.pcd.2019.08.005.","journal-title":"Prim Care Diabetes"},{"issue":"4","key":"6031_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1142\/S0192415X19500393","volume":"47","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhang J, Feng R, Jin X, Yang F, Ji Z, et al. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: a systematic review and meta-analysis of randomized controlled clinical trials. Am J Chin Med. 2019;47(4):751\u201367. https:\/\/doi.org\/10.1142\/S0192415X19500393.","journal-title":"Am J Chin Med"},{"issue":"12","key":"6031_CR29","first-page":"185","volume":"32","author":"Q Weidong","year":"2014","unstructured":"Weidong Q, Jiwei W, Haiting L. Research progress on treatment of hyperlipidemia from phlegm and blood stasis. J Sichuan Tradit Chin Med. 2014;32(12):185\u20137.","journal-title":"J Sichuan Tradit Chin Med"},{"issue":"8","key":"6031_CR30","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1161\/01.CIR.0000139985.81163.CE","volume":"110","author":"S Zhao","year":"2004","unstructured":"Zhao S, Liu L, Cheng Y, Shishehbor M, Liu M, Peng D, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation. 2004;110(8):915\u201320. https:\/\/doi.org\/10.1161\/01.CIR.0000139985.81163.CE.","journal-title":"Circulation"},{"issue":"12","key":"6031_CR31","first-page":"657","volume":"10","author":"H Nan","year":"2012","unstructured":"Nan H. Effect of Zhibituo tablet on hyperlipidemia. Guide China Med. 2012;10(12):657\u20138.","journal-title":"Guide China Med"},{"issue":"20","key":"6031_CR32","first-page":"168","volume":"19","author":"L Chenxi","year":"2019","unstructured":"Chenxi L, Ruixia L. Effect of Zhi Bi Tai Capsule on type 2 diabetes mellitus with hyperlipidemia. World Latest Med Inform. 2019;19(20):168\u20139.","journal-title":"World Latest Med Inform"},{"issue":"15","key":"6031_CR33","first-page":"135","volume":"8","author":"Q Zongsheng","year":"2015","unstructured":"Zongsheng Q. Clinical effect of Qushi Huayu decoction on nonalcoholic fatty liver disease. Chin J Clin Ration Drug Use. 2015;8(15):135\u20136.","journal-title":"Chin J Clin Ration Drug Use"},{"issue":"08","key":"6031_CR34","first-page":"1764","volume":"31","author":"H Li","year":"2013","unstructured":"Li H, Feng Q, Zhu D, Ying H, Li D, Fu Q. Clinical observation of Qushi Huayu decoction in the treatment of nonalcoholic steatohepatitis with phlegm and blood stasis. Chin Arch Tradit Chin Med. 2013;31(08):1764\u20137.","journal-title":"Chin Arch Tradit Chin Med"},{"key":"6031_CR35","doi-asserted-by":"publisher","first-page":"5920485","DOI":"10.1155\/2019\/5920485","volume":"2019","author":"XJ Gou","year":"2019","unstructured":"Gou XJ, Gao S, Chen L, Feng Q, Hu YY. A metabolomic study on the intervention of traditional Chinese medicine Qushi Huayu decoction on rat model of fatty liver induced by high-fat diet. Biomed Res Int. 2019;2019:5920485\u201314. https:\/\/doi.org\/10.1155\/2019\/5920485.","journal-title":"Biomed Res Int"},{"key":"6031_CR36","doi-asserted-by":"publisher","first-page":"6242697","DOI":"10.1155\/2017\/6242697","volume":"2017","author":"XJ Gou","year":"2017","unstructured":"Gou XJ, Feng Q, Fan LL, Zhu J, Hu YY. Serum and liver tissue metabonomic study on fatty liver in rats induced by high-fat diet and intervention effects of traditional Chinese medicine Qushi Huayu decoction. Evid Based Complement Alternat Med. 2017;2017:6242697\u201312. https:\/\/doi.org\/10.1155\/2017\/6242697.","journal-title":"Evid Based Complement Alternat Med"},{"key":"6031_CR37","doi-asserted-by":"publisher","first-page":"184358","DOI":"10.1155\/2013\/184358","volume":"2013","author":"Q Feng","year":"2013","unstructured":"Feng Q, Gou XJ, Meng SX, Huang C, Zhang YQ, Tang YJ, et al. Qushi Huayu decoction inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in vivo and in vitro. Evid Based Complement Alternat Med. 2013;2013:184358\u201314. https:\/\/doi.org\/10.1155\/2013\/184358.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"17","key":"6031_CR38","doi-asserted-by":"publisher","first-page":"27820","DOI":"10.18632\/oncotarget.15482","volume":"8","author":"Q Feng","year":"2017","unstructured":"Feng Q, Liu W, Baker S, Li H, Chen C, Liu Q, et al. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease. Oncotarget. 2017;8(17):27820\u201338. https:\/\/doi.org\/10.18632\/oncotarget.15482.","journal-title":"Oncotarget"},{"issue":"10","key":"6031_CR39","first-page":"937","volume":"31","author":"Z Junren","year":"2016","unstructured":"Junren Z, Runlin G, Guangping Z, Guoping L, Dong Z, Jianjun L. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised in 2016). Chin Circ J. 2016;31(10):937\u201353.","journal-title":"Chin Circ J"},{"issue":"8","key":"6031_CR40","first-page":"716","volume":"23","author":"Z Xuezhi","year":"2008","unstructured":"Xuezhi Z. Diagnosis and treatment standard of dyslipidemia in traditional Chinese medicine (Draft). Chin J Tradit Chin Med. 2008;23(8):716\u20139.","journal-title":"Chin J Tradit Chin Med"},{"issue":"9500","key":"6031_CR41","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Fassett R. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(05)67667-2.","journal-title":"Lancet"},{"issue":"3","key":"6031_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11655-009-9001-x","volume":"15","author":"J Peng","year":"2009","unstructured":"Peng J, Hu Y, Feng Q, Cheng Y, Xu L, Chen S, et al. Effect of Jianpi Huoxue decoction-containing serum on tumor necrosis factor-alpha secretion and gene expression of endotoxin receptors in RAW264.7 cells induced by lipopolysaccharide. Chin J Integr Med. 2009;15(3):198\u2013203. https:\/\/doi.org\/10.1007\/s11655-009-9001-x.","journal-title":"Chin J Integr Med"},{"issue":"04","key":"6031_CR43","first-page":"110","volume":"29","author":"C Yumei","year":"2015","unstructured":"Yumei C. Qushi Huayu decoction combined with western medicine in the treatment of nonalcoholic fatty liver. J Pract Tradit Chin Intern Med. 2015;29(04):110\u20131.","journal-title":"J Pract Tradit Chin Intern Med"},{"issue":"1","key":"6031_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06031-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06031-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06031-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:04:34Z","timestamp":1643778274000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06031-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6031"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06031-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-658452\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the ethics committee in Shuguang Hospital (Ethics approval number: 2019-780-135-01). Patients are included after giving written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We will give informed consent for the publication of the dataset from patients at the point of recruitment to the <i>Trials<\/i>. All the patient details will be strictly confidential. Any information that is published will not reveal the identity of the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}